Due to COVID-19, new study enrollment is being assessed on a case by case basis. If you have any questions please call our central phone number at 616-391-1230.

Brain/CNS Clinical Trials

Narrow List by Age:

(Refer to Clinical Summary for age requirements)

Brain/CNS

Protocol Alliance A071601
Cancer Type: CRANIOPHARYNGIOMAS
Fast Facts

Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas

Please check out the rare protocol list to locate other studies within this disease site.

Protocol NRG BN007
Cancer Type: Unmethylated Glioblastoma
Fast Facts

A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab Versus Temozolomide in Patients With Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma

Please check out the rare protocol list to locate other studies within this disease site.

Protocol N0577
Cancer Type: Codeleted Anaplastic Glioma
Fast Facts

Phase III Intergroup Study of Radiotherapy versus Temozolomide Alone versus Radiotherapy with Concomitant and Adjuvant Temozolomide for Patients with 1p/19q Codeleted Anaplastic Glioma

Please check out the rare protocol list to locate other studies within this disease site.

Protocol Alliance A071401
Cancer Type: MENINGIOMAS WITH SMO/AKT/NF2 MUTATIONS
Fast Facts

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations

Protocol NRG BN003
Cancer Type: MENINGIOMA
Fast Facts

Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma

Please check out the rare protocol list to locate other studies within this disease site.

Protocol Alliance A071701
Cancer Type: Brain metastases
Fast Facts

Genomically-Guided Treatment Trial in Brain Metastases

Protocol Alliance A071801
Cancer Type: Metastatic Brain Disease
Fast Facts

Phase III Trial of Post-Surgical Single Fraction Stereotactic Radiosurgery (SRS) Compared with Fractionated SRS (FSRS) for Resected Metastatic Brain Disease

Please check out the rare protocol list to locate other studies within this disease site.

Protocol ACCRU 2018-01
Cancer Type: Untreated Solid Tumors
Fast Facts

Blood Sample Collection to Evaluate Biomarkers in Subjects with Untreated Solid Tumors

Protocol WF 1801
Cancer Type: Cancer Control
Fast Facts

A Single Arm, Pilot Study of Ramipril for Preventing Radiation-Induced Cognitive Decline in Glioblastoma (GBM) Patients Receiving Brain Radiotherapy

Please check out the rare protocol list to locate other studies within this disease site.

Protocol COG ACNS1422
Cancer Type: Medulloblastoma
Fast Facts

A Phase II Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients

Age - Patients must be Greater than or Equal to 3 Years and Less than 22 Years of Age at the Time of Enrollment on ACNS1422 Step 0.

Protocol COG ACNS1721
Cancer Type: High-Grade Glioma
Fast Facts

A Phase II Study of Veliparib (ABT-888, IND # 139199) and Local Irradiation,Followed by Maintenance Veliparib and Temozolomide, in Patients with Newly Diagnosed High-Grade Glioma (HGG) without H3 K27M or BRAFV600E Mutations

Patients must be ≥ 3 Years and ≤ 25 Years of Age at the Time of Enrollment on Step 0.

Patients >21 Years must be IDH Mutant.

Note: At the time of ACNS1721 Step 1 enrollment, patients will be stratified and age is a factor.

Protocol COG ACNS1723
Cancer Type: High-Grade Glioma
Fast Facts

A Phase II Study of Dabrafenib (NSC# 763760) with Trametinib (NSC# 763093) after Local Irradiation in Newly-Diagnosed BRAFV600-Mutant High-Grade Glioma (HGG) (IND# 145355)

Patients must be ≥ 3 Years and ≤ 25 Years of Age at the Time of Enrollment on Step 0.

Protocol COG ACNS1831
Cancer Type: Low-Grade Glioma
Fast Facts

A Phase III Randomized Study of Selumetinib (IND # 77782) versus Carboplatin/Vincristine in 
Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG)

Patients must be ≥ 2 Years and ≤ 21 Years at the Time of Enrollment.

Protocol COG ACNS1833
Cancer Type: Low-Grade Glioma
Fast Facts

ACNS1833: A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine versus Selumetinib (NSC# 748727, IND# 77782) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) not associated with BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)

Patients must be ≥ 2 years and ≤ 21 years of age at the time of enrollment on ACNS1833 Step 0.

Protocol COG ANBL00B1
Cancer Type: Neuroblastoma-Biology
Fast Facts

Neuroblastoma Biology Studies

All Newly Diagnosed Patients with Suspected Neuroblastoma, Suspected Ganglioneuroblastoma, or Suspected Ganglioneuroma/Maturing Subtype Seen at COG Institutions are Eligible for this Study. 

Please check out the rare protocol list to locate other studies within this disease site.

Cancer clinical trials are research studies for developing better ways of detecting, treating, and eventually preventing cancer. By taking part in a clinical trial, you are among the first to receive new research treatments before they are widely available. Your participation in a clinical trial will influence the future direction of cancer care.

If you are interested in participating in a clinical trial, consult with your physician. Please note: clinical trials are not risk free. Patients must explore the options that are best for their individuals needs with the help of their physician.